<DOC>
	<DOC>NCT00669071</DOC>
	<brief_summary>This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.</brief_summary>
	<brief_title>Treatment w/ Tri-Luma® Cream &amp; Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream &amp; Intense Pulsed Light (IPL) in Melasma</brief_title>
	<detailed_description>Same as above.</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Subjects diagnosed with moderate to severe melasma on both sides of the face (Investigator's Global Assessment (IGA) at baseline must be 3 or 4.) Subjects with a diagnosis of skin cancer (Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), Melanoma) in the areas to be treated Subjects with prior facial Intense Pulsed Light (IPL), resurfacing, deep or chemical peels within 6 months of the date of study entry Subject has initiated treatment with hormones including estrogen, progesterone and/or oral contraceptives within 3 months of study entry, or who intend to discontinue hormonal therapy during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>